Evidence map›Paper›PMID 36251675›Full record

ArticlePloS one2022

Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.

Martha Sedegah, Chad Porter, Emilie Goguet, Harini Ganeshan, Maria Belmonte, Jun Huang, Arnel Belmonte, Sandra Inoue, Neda Acheampong, Allison M W Malloy and 16 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Advanced Human Immune Cell-Organoid Co-Cultures for Functional Testing of Cancer Nanovaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 1 country.

Martha SedegahAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
Chad PorterTranslational Clinical Research Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
Emilie GoguetDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.ORCID 0000-0001-6284-4346
Harini GaneshanAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
Maria BelmonteAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.ORCID 0000-0002-4103-6611
Jun HuangAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
Arnel BelmonteAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
Sandra InoueAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
Neda AcheampongAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
Allison M W MalloyDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Monique Hollis-PerryClinical Trials Center, Naval Medical Research Center, Silver Spring, MD, United States of America.ORCID 0000-0002-7130-9772
Belinda Jackson-ThompsonDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Kathy F RamseyGeneral Dynamics Information Technology, Falls Church, VA, United States of America.
Yolanda AlcortaGeneral Dynamics Information Technology, Falls Church, VA, United States of America.
Santina E MaiolatesiHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
Gregory WangGeneral Dynamics Information Technology, Falls Church, VA, United States of America.
Anatolio E ReyesGeneral Dynamics Information Technology, Falls Church, VA, United States of America.
Luca IllinikHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
Margaret Sanchez-EdwardsHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
Timothy H BurgessInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Eric D LaingDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Simon D PollettHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
Eileen VillasanteAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
Edward MitreDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Michael R HollingdaleAgile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.ORCID 0000-0002-2343-3824
Naval Medical Research Command · USHenry M. Jackson Foundation · USUniformed Services University of the Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection SARS-CoV-2 T-cell responses are associated with COVID-19 recovery and protection, but the precise role of T-cell responses remains unclear, and how post-infection vaccination ('hybrid immunity') further augments this immunity To accomplish these goals, we studied healthy adult healthcare workers who were (a) uninfected and unvaccinated (n = 12), (b) uninfected and vaccinated with Pfizer-BioNTech BNT162b2 vaccine (2 doses n = 177, one dose n = 1) or Moderna mRNA-1273 vaccine (one dose, n = 1), and (c) previously infected with SARS-CoV-2 and vaccinated (BNT162b2, two doses, n = 6, one dose n = 1; mRNA-1273 two doses, n = 1). Infection status was determined by repeated PCR testing of participants. We used FluoroSpot Interferon-gamma (IFN-γ) and Interleukin-2 (IL-2) assays, using subpools of 15-mer peptides covering the S (10 subpools), N (4 subpools) and M (2 subpools) proteins. Responses were expressed as frequencies (percent positive responders) and magnitudes (spot forming cells/106 cytokine-producing peripheral blood mononuclear cells [PBMCs]). Almost all vaccinated participants with no prior infection exhibited IFN-γ, IL-2 and IFN-γ+IL2 responses to S glycoprotein subpools (89%, 93% and 27%, respectively) mainly directed to the S2 subunit and were more robust than responses to the N or M subpools. However, in previously infected and vaccinated participants IFN-γ, IL-2 and IFN-γ+IL2 responses to S subpools (100%, 100%, 88%) were substantially higher than vaccinated participants with no prior infection and were broader and directed against nine of the 10 S glycoprotein subpools spanning the S1 and S2 subunits, and all the N and M subpools. 50% of uninfected and unvaccinated individuals had IFN-γ but not IL2 or IFN-γ+IL2 responses against one S and one M subpools that were not increased after vaccination of uninfected or SARS-CoV-2-infected participants. Summed IFN-γ, IL-2, and IFN-γ+IL2 responses to S correlated with IgG responses to the S glycoprotein. These studies demonstrated that vaccinations with BNT162b2 or mRNA-1273 results in T cell-specific responses primarily against epitopes in the S2 subunit of the S glycoprotein, and that individuals that are vaccinated after SARS-CoV-2 infection develop broader and greater T cell responses to S1 and S2 subunits as well as the N and M proteins.

Indexed as

COVID-19Interferon-gammaInterleukin-22019-nCoV Vaccine mRNA-1273AdultAntibodies, ViralBNT162 VaccineEpitopesHumansImmunoglobulin GLeukocytes, MononuclearProteomeSARS-CoV-2Vaccination2019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineEpitopesImmunoglobulin GInterferon-gammaInterleukin-2Proteome

Identifiers

PMID36251675
PMCPMC9576055
OpenAlexW4306631504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.